Timothy Affolter

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index879citations80works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(38), Monoclonal and Polyclonal Antibodies Research(29), Protein Kinase Regulation and GTPase Signaling(21), Computational Drug Discovery Methods(17), Advanced Proteomics Techniques and Applications(12)

Publications80 total

Supplementary Figure S4 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Methods from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure S6 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure S5 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure S1 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure S7 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Table S1 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure S3 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure S2 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Table S2 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2025Open Access
Supplementary Figure 2 from <sup>18</sup>F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
2025Open Access
Supplementary Figure 3 from <sup>18</sup>F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
2025Open Access
Supplementary Tables from <sup>18</sup>F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
2025Open Access
Data from <sup>18</sup>F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
2025Open Access
Supplementary Figure 4 from <sup>18</sup>F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
2025Open Access
Supplementary Figure 1 from <sup>18</sup>F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
2025Open Access
18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors
Molecular Cancer Therapeutics·2025· 3 citedOpen Access
Supplementary Figure S7 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2024Open Access
Supplementary Figure S2 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2024Open Access
Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Anand Giddabasappa(34), Ziyue Karen Jiang(33), Sripad Ram(33), Kavon Noorbehesht(33), Lisa K. Manzuk(33), Catherine Lee(29), Simon Planken(29), Roberto Ortiz(29), Michael Hall(29), Gabriel E. Troche(29), Nathan T. Ihle(29), Theodore Johnson(29), Youngwook Ahn(29), Manfred Kraus(28), Patrick B. Lappin(10), Cathy C. Zhang(8), James G. Christensen(7), Tim Nichols(6), Zhengming Yan(6), Kyle Kuszpit(6)